Delivering Unprecedented Access to Biosimilars in Global Markets
CONTACT  |  SITE MAP
  • Building a pure-play, sustainable and profitable
    biosimilar business
  • Improving patient access to important, cost-effective
    medicines worldwide
  • Advancing our products through strategic partnerships
    to maximize future value
Who We Are

EPIRUS is a biopharmaceutical company focused on building a pure-play, sustainable and profitable biosimilar business by improving patient access to cost-effective medicines worldwide. Currently, we are progressing a pipeline of three monoclonal antibodies for autoimmune / inflammatory conditions. Our focus is to effectively navigate the diverse regulatory, legal and commercial global landscape for biosimilars through strategic partnerships which will maximize future value.

Learn More

News

August 7, 2015

EPIRUS Biopharmaceuticals Reports Second Quarter 2015 Financial Results

August 4, 2015

EPIRUS Biopharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

Events

August 11, 2015

EPIRUS Presents at Wedbush PacGrow Healthcare Conference

July 14, 2015

EPIRUS Announces Profit-Sharing Collaboration with Polpharma Group

Bookmark and Share